Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.

The state’s largest commercial health insurer will stop covering a popular class of prescription drugs for weight loss, ...

The use of GLP-1 meds — made popular by Ozempic (NVO) — among U.S. adults without diabetes more than tripled between 2018 and 2022, with annual spending surging from $1.6 billion to $5.8 billion.

Novo Nordisk, the maker of Ozempic and Wegovy, has also jumped into the legal fight —this time by intervening in the OFA’s lawsuit against the FDA. The company supports the agency’s move to restrict ...

Eli Lilly and Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot.

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

The company's breakthrough puts the market one step closer to having an injection-free alternative for the treatment of ...

Eli Lilly’s latest innovation, orforglipron, has emerged as a formidable contender in the weight-loss medication arena. The pill has demonstrated comparable results to Ozempic, a leading injectable ...

What is 'Ozempic feet'? Side effect of the weight-loss drug revealed - Some people have reported they find standing or ...

Driven by a surge in demand, Ozempic shortages have been ongoing worldwide since 2022, when the drug’s popularity as a weight-loss method became pervasive. This raised concerns among health care ...

The drugmaker Lilly announced topline results of a clinical trial of a new pill in the same drug class as injectables like ...